Last reviewed · How we verify
Metronidazole 0.75% cream
Metronidazole disrupts bacterial and protozoal DNA, leading to cell death and reduction of microorganisms associated with rosacea and other inflammatory skin conditions.
Metronidazole disrupts bacterial and protozoal DNA, leading to cell death and reduction of microorganisms associated with rosacea and other inflammatory skin conditions. Used for Rosacea (topical treatment), Bacterial vaginosis (systemic formulations; topical cream may be used off-label).
At a glance
| Generic name | Metronidazole 0.75% cream |
|---|---|
| Also known as | Metronidazole |
| Sponsor | Galderma R&D |
| Drug class | Nitroimidazole antimicrobial |
| Target | Microbial DNA (non-selective) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Metronidazole is a nitroimidazole antimicrobial that generates reactive oxygen species and damages microbial DNA, resulting in bactericidal and antiprotozoal effects. In rosacea, it reduces the population of Demodex mites and associated bacteria, thereby decreasing inflammation and erythema. The topical 0.75% cream formulation delivers the drug directly to affected skin areas.
Approved indications
- Rosacea (topical treatment)
- Bacterial vaginosis (systemic formulations; topical cream may be used off-label)
Common side effects
- Local irritation or burning at application site
- Dryness or peeling
- Metallic taste (systemic absorption)
- Contact dermatitis
Key clinical trials
- Pharmacokinetics of Transdermal Metronidazole (PHASE4)
- Preferences & Treatment Satisfaction Drivers in Rosacea Patients
- Effect of Antibiotics on Penile Microbiome and HIV Susceptibility Study in Ugandan Men (NA)
- CD5024 1% [Ivermectin 1%] Cream Versus Metronidazole 0.75% Cream in Papulopustular Rosacea (PPR) Study (PHASE3)
- Study to Evaluate the Efficacy and Safety of PAC-14028 Cream in Rosacea Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metronidazole 0.75% cream CI brief — competitive landscape report
- Metronidazole 0.75% cream updates RSS · CI watch RSS
- Galderma R&D portfolio CI